

GRADUATE CERTIFICATE IN HEALTH PRODUCTS REGULATION

PHARMACEUTICALS AND MEDICAL DEVICES

CENTRE of REGULATORY EXCELLENCE



CoRE

**Centre of Regulatory Excellence
@ Duke-NUS Medical School**

VISION

To be a leading Centre enhancing regulatory capability and scientific excellence for health products and systems in Asia

EXECUTIVE DIRECTOR'S MESSAGE



PROFESSOR JOHN LIM

Executive Director
Centre of Regulatory Excellence

Core Lead (Policy)
SingHealth Duke-NUS Global Health Institute

Senior Advisor
Ministry of Health, Singapore

Chairman
Consortium for Clinical Research & Innovation, Singapore

CoRE was established in 2014 in recognition of the need to grow the local and regional pool of regulatory talent, as part of the wider aim to strengthen regional regulatory systems for health-related products in Asia-Pacific. We believe that robust regulatory systems must be supported by skilled regulatory professionals equipped with up-to-date regulatory knowledge and critical skills to navigate the fast evolving and complex global regulatory environment. Structured regulatory training programmes with a focus on issues relevant to Asia and the Asia-Pacific region are essential to meeting this need as well as developing a talent pool of regulatory leaders.

We are pleased to offer the Graduate Certificate in Health Products Regulation – the first dedicated regulatory training that caters to your learning needs in Singapore, South-East Asia and Asia-Pacific – for regulatory professionals as well as healthcare professionals and researchers interested to know more about regulatory science. We welcome you to consider this opportunity to develop your knowledge and skills to advance your regulatory career and your effectiveness as a regulatory professional.

MISSION

To establish regional platforms and networks to grow competencies, enhance collaboration and promote thought leadership in innovative regulatory science and health policy



CoRE provides a neutral academic platform for networking of health products regulatory stakeholders in the Asia-Pacific, with a special focus on South-East Asia, to promote capacity development and innovation.

DEPUTY DIRECTOR'S MESSAGE



ASSOCIATE PROFESSOR SILKE VOGEL

Deputy Director
Centre of Regulatory Excellence

Senior Associate Dean
Graduate Studies
Duke-NUS Medical School

Education is one of CoRE's key strategic thrusts as it works towards enhancing regional health systems in Asia-Pacific. Taking on the Duke-NUS learning philosophy, we recognise that an effective learning experience goes beyond increasing knowledge and understanding, but also develops advanced technical skills and soft skills such as critical thinking and problem-solving skills. These are important traits to be found in regulatory professionals, given the increasing complexity and emerging challenges in the regulatory landscape.

We encourage you to explore the opportunities offered by the Graduate Certificate Programme, including a rich and fulfilling learning experience that equips you with the necessary knowledge and skills for a rewarding career in pharmaceutical regulatory affairs.

ABOUT DUKE-NUS

**Duke-NUS is a partnership
between Duke University
and the National
University of Singapore.**



In 2005, with firm support from the Singapore government, the National University of Singapore (NUS) and Duke University, two academic institutions with strong track records in research and education, committed to combine the unique medical education curriculum at Duke University School of Medicine with the academic rigour and rich resources offered by NUS, and to offer students an enriching and innovative educational experience.

Duke-NUS is located on the main campus of the largest healthcare group in the country, Singapore Health Services (SingHealth). This group collectively delivers multi-disciplinary care among 42 clinical specialties across a large network of hospitals, national specialty centres and polyclinics. Together, Duke-NUS and SingHealth constitute a leading, world class Academic Medical Centre embodying the goal of delivering the highest levels of patient care, education and research.

ABOUT CoRE

CoRE was established to facilitate access to safe, high quality and effective medicines and medical devices through the strengthening of health product regulatory systems in the Asia-Pacific, with a special focus on South-East Asia.



Guided by this theme, CoRE contributes to improving patient access to health products and also enhancing regional health systems and health security.

Launched in 2014 within Duke-NUS, CoRE engages and supports its stakeholders through the approaches of education, to enhance the competencies of regulatory professionals, think tank, to promote thought leadership and policy innovation, and to leverage on our expertise and networks to provide advisory support for our stakeholders.

CoRE's education activities serve as a key focus towards enhancing regulatory capabilities. Continuous, structured regulatory educational opportunities are necessary to enable stakeholders to keep pace with rapid advancements in technology, healthcare systems and the biomedical landscape. It is particularly important to address regulatory capacity needs to facilitate timely access to health products and to support the flourishing biomedical scene in Singapore and the Asia-Pacific.

CoRE aims to address these needs through the Graduate Certificate Programme in Health Products Regulation that is focused on the needs of the Asia-Pacific region. CoRE offers this programme within a neutral academic setting to facilitate learning, networking and collaboration, encouraging the growth of a community committed to regulatory excellence.

STRATEGIC WAY TO DEVELOP YOUR CAREER

Through this Graduate Certificate Programme we aim to equip working professionals like yourself with updated scientific and regulatory knowledge and critical skills through application-based learning. The skillsets gained through this programme will help you assume diverse roles requiring regulatory science expertise within the public and private sectors.

An enhanced understanding of regulatory issues will better prepare you to facilitate innovation and health products development as well as provide a deeper appreciation of the basis of regulatory requirements, contributing to timely research and marketing authorisation decisions to support the healthcare systems.

BROADEN YOUR WORLDVIEW

Guided by the Duke-NUS and CoRE education philosophy, the programme aims not only to impart knowledge and understanding, but also to facilitate significant networking amongst regulators, industry and other stakeholders. You will have the opportunity to meet international and regional experts with different backgrounds and these interactions will expand your worldview by providing global and regional insights and enhancing your understanding of different perspectives.

The curriculum will promote interdisciplinary inquiry and cover different skill sets and technical areas. Graduates will be more adept at effectively working and communicating within a team with an international outlook, given the diverse and international backgrounds of course participants.



The Graduate Certificate curriculum is designed to expand your core skills and expose you to new competencies in pharmaceutical and medical device regulation.




We are committed to providing a holistic learning experience through a robust curriculum which is structured to:

DEVELOPING ADEPT PROFESSIONALS



The programme is targeted at professionals from the public and private sectors who wish to enhance their regulatory competencies. It is suitable for professionals from the healthcare and regulatory sector, including biomedical researchers, product developers and policy makers who are interested in gaining insights on the impact and contributions of regulatory science to the wider healthcare environment.



Insights from
Asia-Pacific Leads

Cutting-Edge Topics

Valuable Networking
Opportunities

Robust Foundation

Product Life Cycle
Approach

Powered by
Global Thought Leaders



IMPROVE

...technical competencies and understanding of the guidelines that influence key regulatory processes



FACILITATE

...interaction and collaboration by providing opportunities for students to interact with regulatory stakeholders from different professional backgrounds and countries



NURTURE

...critical thinking skills of students to enable quality in regulatory decision-making across the product life cycle



DR MARGARET HAMBURG

Chairperson

Centre of Regulatory Excellence

Foreign Secretary

U.S. National Academy of Medicine

Former Commissioner

U.S. Food and Drug Administration

“ To enable participants to make the greatest impact through their individual roles, CoRE’s curriculum is enriched with invaluable guidance and real-world insights from global and regional thought leaders in regulatory affairs.

”



GRADUATE CERTIFICATE IN PHARMACEUTICAL REGULATION

Duke-NUS Medical School

PATH TO SUCCESS

As an advocate for continuous learning, we are excited to partner with you on your career development journey. To ensure that you are exposed to the full scope of knowledge, skills, and competencies for your career development, the course content is structured to broaden your perspectives and provide a holistic view of the regulatory ecosystem. Given the rise in significance of health products regulations in the healthcare industry, it aims to deepen your understanding of the science underlying health product regulation and regulatory frameworks, which includes pharmaceuticals, advanced therapies, biologics, as well as medical technology that cuts across devices, diagnostics and software applications. It will also provide you with a practical and realistic view of what regulatory science involves through interactions with experts and practitioners from industry and national regulatory authorities.

Through the course modules, you will strengthen your

foundations in regulatory science and gain an enhanced understanding of the basis for managing regulatory submissions and processes, and making quality regulatory decisions. Review and discussion of cutting-edge scientific and regulatory topics will empower you to facilitate the development of regulatory strategy and policy, and strengthen your regulatory leadership capabilities.

To meet the objectives of the programme and achieve the learning outcomes, the Duke-NUS pedagogy framework has been incorporated. This pedagogy is an integration of lectures and Team-Based Learning, creating a novel approach that fosters the development of lifelong learners, problem solvers and critical thinkers. Emphasising the Duke-NUS Educational Philosophy, this framework promotes continuing education while offering the flexibility and accessibility required by working regulatory professionals.

STAY AHEAD

The curriculum is tailored to be relevant, contemporary, and accessible through an emphasis on three themes that run across all the modules to:



ENHANCE

...proficiency in regulatory submissions and reviews across product life cycle, and support good regulatory management and quality in decision-making.



SUPPORT

...innovation of product development and regulatory processes for timely access to new health products.



PROMOTE

...convergence, collaboration and partnership across stakeholders for an efficient and effective regulatory environment.


Building on these common themes, the programme will provide you with the relevant skillsets and mindset to deepen your understanding and lead you through the modules. With an emphasis on 'how to', you will leave with actionable plans on how to:

- Use knowledge of various regulatory systems and principles of product life cycle management to support quality decision-making in your organisation
- Leverage current regulatory platforms and resources to adopt and implement good regulatory practices
- Relate technical datasets to regulatory requirements and support good practices
- Advocate the role and contributions of regulatory professionals to the wider healthcare system

CURRICULUM

The programme structure below outlines the 4 subject areas you will focus on. To graduate, you will be required to complete a total of 4 modules out of the 11 modules offered.

Students have the flexibility to choose from any subject area of interest.



The flexible curriculum is designed to accommodate your busy work schedule, allowing you to plan your course of career development to meet your needs and interests. The programme is taught with a blended learning approach, engaging students through an online

learning management system that delivers content, enables assessments, and allows for interaction. Each module will also feature a 5-day face-to-face workshop, specifically designed to accommodate the demanding work schedule of your full-time job.

ASSESSMENT MODE

Activities during the course will be graded to fulfil academic requirements. Each course module will include formal and informal assessments guided by the Duke-NUS teaching pedagogy. You will be graded on individual and group tests as well as group presentations during class discussions.

Candidature

The module credits which are valid for a period of five years, will provide the necessary flexibility for planning your schedule to complete this course, based on your work commitment.

Continuation and Graduation Requirements

If unable to complete or pass a module, you are allowed to re-take the module once. You may also choose to take a different module if applicable within the Graduate Certificate course.








Guest of Honour, Minister for Health Mr Gan Kim Yong (center) congratulates the inaugural graduating cohort of the Graduate Certificate Programme in Pharmaceutical Regulation, as they receive their certificates from Dean of Duke-NUS Medical School, Professor Thomas Coffman (center left) and Executive Director of CoRE, Professor John Lim (center right) during CoRE's 5th Anniversary Dinner.

COURSE DETAILS



FUNDAMENTALS

FUNDAMENTALS OF PHARMACEUTICAL REGULATION

GMS5011 • 4 MODULAR CREDITS

Regulation of health products – pharmaceuticals, biotherapeutics, advanced therapies and medical technology - is controlled by standards, guidelines and legal frameworks. The interactions among the stakeholders – industry, regulatory authorities, healthcare professionals and patients – are required for the effective governance for safe, quality and efficacious health products and timely access for patients.

This fundamental module provides the understanding of the contributions of the various stakeholders, functions and guidelines that shape the regulatory environment and impact the healthcare management scene. The concept of product lifecycle will be also be explored among other contemporary regulatory approaches.

Learning Outcomes:

- Explain the basis of regulatory functions and the operational processes across the product life cycle for health products
- Describe the basic documentation required for regulatory submission and assessment, based on global dossier formats
- Describe the interaction among the regulatory stakeholders and the implication on regulatory decision-making
- Describe the various platforms of regulatory interactions and the major contributions in shaping regulatory approaches and collaborations



PRE-MARKET PROCESSES

CHEMISTRY, MANUFACTURING AND CONTROLS

GMS5012 • 4 MODULAR CREDITS

Ensuring quality of healthcare products, is one of the key pillars in regulatory responsibilities for industry, manufacturers and regulators. The contribution of Chemistry, Manufacturing and Controls (CMC) to a successful control of quality in pharmaceutical products spans from product development and manufacture, process validation to post-market variation changes, as well as an optimal quality management system.

This module provides the foundation in understanding the regulatory science behind the development, manufacturing and control of pharmaceuticals, including the global guidances that shape the regulatory processes. Besides promoting good submissions and evaluation practices, the module aims to enhance regulatory convergence and cooperation on CMC regulation.

Learning Outcomes:

- Explain the domains and key requirements for CMC dossier information and assessment of pharmaceuticals
- Apply principles of ICH quality guidelines across various CMC datasets, including processes for life cycle management
- Identify the common areas of concerns in the CMC regulation, including issues of regulatory divergence and country specific requirements

CLINICAL TRIAL DESIGNS AND DATA ANALYSIS

GMS5101 • 4 MODULAR CREDITS

The effective regulation of pharmaceuticals for safety and efficacy depends on the availability, understanding and appropriate implementation of relevant guidelines and the processes designed to ensure quality in decision-making. The requirements are frequently different from traditional clinical trials and specific to regulatory affairs.

This module provides the understanding for the unique requirements of clinical trials and clinical data meant to support regulatory evaluation and approvals.

Learning Outcomes:

- Describe the key requirements of clinical studies for regulatory approvals
- Explain the key requirements for the non-clinical and clinical dossier information and assessment of pharmaceuticals across the product life cycle
- Explain the basis of structured decision-making in benefit-risk assessment and communication



REGULATORY TRENDS

REGULATION OF CELL, TISSUE AND GENE THERAPIES

GM55103 • 4 MODULAR CREDITS

Advanced therapies, covering the scope of cellular, tissue and gene treatment modalities, is a rapidly advancing field that offers exciting new therapeutic possibilities and constantly challenges the regulatory environment to expedite access to these innovations.

Through this module, an understanding is gained on the various frameworks and practices regulating advanced therapies, including requirements for product evaluation and dossier submission for an effective product life cycle management. The module will interest students who are keen in global trending regulatory approaches and strengthening the skillsets to accommodate new innovation. There is also a focus on promoting convergence of regulatory approaches for advanced therapies.

Learning Outcomes:

- Describe the concepts of regulation of Advanced Therapies, covering cell, tissue and gene modalities for healthcare management
- Explain the differences among the various existing regulatory frameworks and regional requirements, as well as opportunities for convergence
- Explain the key requirements for the assessment of advanced therapies across the product life cycle

BIOTHERAPEUTICS AND BIOSIMILARS

GM55104 • 4 MODULAR CREDITS

The advent of biotherapeutics and biosimilars highlighted the need for regulatory affairs to accommodate the rapidly evolving medical sciences, necessitating timely revisions in policies, processes and the technical knowledge in managing these new innovations and facilitating access to meet medical needs.

This module provides the background to the rise of these biologicals in healthcare, and the defining differences from traditional pharmaceuticals and generics. There is a focus on post-market activities which serve as the main guards for ensuring the safe use of these products.

Learning Outcomes:

- Describe the principles supporting the development and regulatory evaluation of biotherapeutics and biosimilars
- Evaluate and comment on the adequacy of data for the submission and assessment of biotherapeutics
- Identify the common areas of concerns in the regulation of biotherapeutics and biosimilars, in the context of pharmacovigilance and product life cycle management



GENERIC MEDICINES

GM55105 • 4 MODULAR CREDITS

Generic medicines are becoming increasingly important as a means of providing access to affordable healthcare by helping to suppress rising healthcare costs.

This module aims to equip students with skills to assess the therapeutic equivalence of a generic medicinal product relative to a comparator, specifically with respect to bioavailability (BA) and bioequivalence (BE). Students will learn how to design and conduct appropriate bioavailability and bioequivalence studies in accordance with established international guidance documents, and to analyse the data from such studies.

Learning Outcomes:

- Explain the principles and regulatory requirements for a generic medicinal product and how they differ from those for an innovator product
- Define fundamental principles of pharmacokinetics, bioavailability, bioequivalence and biowaivers.
- Describe approaches and considerations when assessing bioequivalence for different dosage forms and special considerations

REGULATION OF DIGITAL HEALTH PRODUCTS

GM55106 • 4 MODULAR CREDITS

In today's digital world, technologies and software play an increasingly important role in healthcare management - diagnosis, treatment, patient monitoring and Real World Data collection. While software-based medical devices products are currently controlled via medical device regulation, they differ significantly from traditional medical devices requiring a more streamlined and efficient regulatory oversight. Software standards and guidelines published by standards development organisations (eg., ISO, IEC) and regulatory agencies/forums are important tools for effective governance for safe, quality and efficacious health products and timely access for patients.

This module provides the foundation in understanding established standards, guidelines and regulatory principles on conformity assessment of medical device softwares.

Learning Outcomes:

- List and describe the relevant standards and guidances required in Digital Health products verification and validation
- Describe regulatory activities through medical device software development, testing and documentation
- Describe key regulatory considerations in the product life cycle including change management and post-market activities

IN VITRO DIAGNOSTIC DEVICES AND PRECISION MEDICINE


GM55107 • 4 MODULAR CREDITS

In Vitro Diagnostic Medical Devices (IVDs) are a key component of healthcare, and pivotal to advancing technology solutions for patient centric care, such as precision medicine and companion diagnostics. This module covers an overview of the technical documentation and available international standards for IVDs, providing a fundamental understanding of the principles behind effective regulation of IVDs.

This module provides the foundation in IVDs regulatory principles, use in precision medicine and companion diagnostics. It also provides an introduction to standards and guidelines playing a pivotal role in meeting requirements to ensure product safety, quality and performance.

Learning Outcomes:

- Describe key regulatory requirements of IVDs through the total product life cycle
- Explain the conformity assessment methods by major and authorities
- Identify the relevant standards and its role in product design verification and validation for regulatory submissions
- Describe the key considerations in change management and post-market activities of IVDs
- Explain the regulation of IVDs in precision medicine and companion diagnostics



POST-MARKET PROCESSES

PHARMACOVIGILANCE: PRINCIPLES AND FRAMEWORKS

GMS5111 • 4 MODULAR CREDITS

Pharmacovigilance is one of the key regulatory function that monitors the safe effective use of pharmaceuticals in the real-world healthcare setting. It has progressively included risk management planning, which encompasses appropriate drug use, signal detection and other risk minimisation activities, for better product life cycle management.

Within this module, the principles, frameworks and processes for pharmacovigilance will be introduced. Various platforms and partnerships among regulatory stakeholders for ensuring adequate and quality pharmacovigilance data will be also covered.

Learning Outcomes:

- Explain the guidelines and principles behind the regulatory frameworks and processes for pharmacovigilance and risk management plan
- Describe the ideal conditions, processes and systems to optimise data collection, collation and signal generation
- List the platforms and initiatives that is supporting pharmacovigilance and risk management, both regionally and globally
- Describe strategies for improving risk communication and stakeholder engagement

POST-MARKET SURVEILLANCE AND ENFORCEMENT

GMS5113 • 4 MODULAR CREDITS

The assurance of safe and quality medicines in the market depends on a range of vital activities after the approval of a medicine by the authorities. This includes the continual monitoring offered by inspections and audits of facilities and testing of product quality. In this globalised environment, there is also an increasing need to leverage on networks to effectively detect lapses in product quality and services in a timely manner.

Key activities and roles essential for effective post-market control, will be introduced, including managing failures of conformance and compliance. Topics covered will include collaborations and networks for optimising post-market communications, and handling of substandard and falsified pharmaceuticals.

Learning Outcomes:

- Describe the regulatory activities required to ensure the safe, quality and efficacious use of medicines after entry into market
- Explain the contribution of post-market activities to product life cycle management
- List the platforms and initiatives that are supporting post-market activities for timely regulatory interventions

POST-MARKET FOR MEDICAL TECHNOLOGIES

GMS5114 • 4 MODULAR CREDITS

Post market vigilance is a key regulatory function in the total product life cycle. Continual monitoring and reporting of medical device adverse events is critical in ensuring the marketed devices are free from unacceptable risk.

This module introduces the key activities and roles essential for effective post-market vigilance, including adverse events, field safety correcting action and change management.

Learning Outcomes:

- Describe the post-market regulatory requirements of medical devices
- Explain the activities involved in Adverse events and Field safety corrective action
- Describe the benefit-risk assessment of manufacturer's Corrective Action Preventive Action (CAPA).
- Explain key regulatory considerations in product changes from safety issues
- List harmonised guidance documents related to post-market vigilance



PROFESSOR GUIDO RASI

Executive Director

European Medicines Agency

Advisory Board Member

Centre of Regulatory Excellence

“

The Graduate Certificate students emerge from the Programme as learned, well-equipped, future-ready individuals, armed with the latest skills and knowledge to meet the demands of a rapidly changing regulatory landscape.

”



HEAR FROM OUR STUDENTS

“

This course presented some real-life problems with the “current & practical” solutions and thought processes to resolve those challenges, and not just simply some textbook answers. What I appreciate most was the experts sharing their train of thought to identify, dissect, and analyse all the post-market surveillance challenges.

“

The content was good, well organised, with good speakers. The practicum helped us to understand the topics better.

“

Although I completed the Programme in 2018-2019, I still refer back to the clear and concise presentation files that was prepared for our online course work - when necessary in the line of my work. The more simplified and smooth the lecture comes through, the greater must be the work behind the scenes. Kudos to the team!

READY TO LEAD FROM ASIA- PACIFIC

The Certificate Programme meets the need for a dedicated regulatory training programme in Asia-Pacific, as currently available training opportunities are mostly catered to learners in the U.S. and Europe. With a curriculum designed to meet specific regional needs, as well as being based in Singapore, students will be able to gain relevant knowledge to serve the needs of their respective countries while appreciating the increased accessibility to training opportunities and flexibility offered by the curriculum model. We envision new generations of skilled and confident professionals equipped to make science-based and quality regulatory decisions for a positive impact on healthcare.



INTERNATIONALLY R

CoRE's academic setting, prominent reputation and strong international networks enable us to engage key opinion leaders as our external experts, faculty and speakers. They come from national regulatory authorities, noted companies, government agencies and industry associations.

These experts are recognised for their extensive real-world experience and contributions to regulatory and healthcare excellence. As a student, you will have the opportunity to engage with them in workshops, seminars, symposiums and conferences.



DR MURRAY LUMPKIN

Deputy Director
Integrated Development Lead &
Global Regulatory Systems Initiatives
Bill & Melinda Gates Foundation
Visiting Expert, CoRE



DRA LUCKY SLAMET

Former Head
National Agency of Food
and Drug Control
Indonesia
Visiting Expert, CoRE



DR JOHN RICHARD THORNBAC
Chief Operating Officer

Diagnostics Development Hub Exploit
Technologies Pte Ltd
Agency for Science, Technology and
Research



DR MOHEB NASR

Principal
Nasr Pharma Regulatory
Consulting
Visiting Expert, CoRE



DR DAPHNE LIN

Deputy Director
Division of Biometrics IV
Office of Biostatistic
Center for Drug Evaluation and
Research
U.S. Food and Drug Administration



MR VIMAL SACHDEVA

Senior Inspector
Prequalification Team
Regulation of Medicines and Other
Health Technologies
Essential Medicines and Health
Products
Health Systems and Innovation
World Health Organization



MR WONG KUM CHEUN

Head Asia Pacific
Regulatory & Development Policy
Novartis Asia Pacific
Pharmaceuticals Pte Ltd
Visiting Expert, CoRE



DR CYNTHIA SUNG

Research Program Manager
Translational Sciences
Global Health
Bill & Melinda Gates Medical Research
Institute
Adjunct Appointment, CoRE



DR FOUAD ATOUF

Vice President
Science — Global Biologics
The United States Pharmacopeia
Visiting Expert, CoRE



DR HENRIKE POTTHAST

Biopharmaceutics Expert
Pharmacokinetics Federal Institute for
Drugs and Medical Devices
Germany

RECOGNISED EXPERTS



DR PATRICK CELIS
Scientific Administrator
(CAT Secretariat)
European Medicines Agency



DR TOMAS SALMONSON
Partner
EMA Consilium Salmonson
& Hemmings
Sweden
Visiting Expert, CoRE



DR RUTH SAVAGE
Consultant & Senior Advisor
Uppsala Monitoring Centre
Senior Lecturer
University of Otago
New Zealand



MR MICHAEL GROPP
Former Chair
RAPS
Global Advisory Council
Advisory Board, CoRE



DR JAN WELINK
Chair
Pharmacokinetics Working Party
European Medicines Agency
Senior Clinical Assessor
Medicines Evaluation Board (MEB)



DR ADELHEID SCHNEIDER
Regional Head
Regulatory and Quality
Roche Diagnostics



DR JEAN-CHRISTOPHE DELUMEAU
Head
Pharmacovigilance
Policy Strategy (Global)
Bayer
Visiting Expert, CoRE



DR-ING STEPHAN ROENNIGER
Adjunct Assistant Professor
George Washington University
Director
Quality External Affairs, Amgen
Visiting Expert, CoRE




DR SETHURAMAN RAMA
Director
Medical Devices Branch
Medical Devices Cluster
Health Products Regulation Group
Health Sciences Authority
Visiting Expert, CoRE



DR KELLATHUR SRINIVASAN
Director
Advanced Therapy Products Branch
Medicinal Products Pre-market
Cluster
Health Products Regulation Group
Health Sciences Authority
Adjunct Appointment, CoRE



DR SANNIE CHONG
Asia Pacific Technical Regulatory
Policy
Global Regulatory Policy Group
Roche Singapore Technical
Operations Pte Ltd
Visiting Expert, CoRE



DR YOSHIAKI MARUYAMA
Review Director
Office of Cellular and Tissue-based
Pharmaceuticals and Medical Devices
Agency
Japan



CONNECT WITH US

Duke-NUS Centre of Regulatory Excellence
8 College Road
Singapore 169857



+65 6601 5147



CoRE@duke-nus.edu.sg



[CoREdukeNUS](https://www.facebook.com/CoREdukeNUS)



[centre-of-regulatory-excellence](https://www.linkedin.com/company/centre-of-regulatory-excellence)



[CoREDukeNUS](https://www.instagram.com/CoREDukeNUS)

For more details, please scan QR code

